文献速递药疹与重症皮肤不良反应autoimm银屑病与炎症性皮肤病

生物制剂治疗皮肤科急症的综合综述

Biologic therapies for dermatologic emergencies: A comprehensive review.
PubMed 文献 · J Am Acad Dermatol · 2025-10-17

本综述聚焦伴嗜酸性粒细胞增多和系统症状的药疹、Stevens-Johnson综合征/中毒性表皮坏死松解症、寻常型天疱疮及泛发性脓疱型银屑病,探讨生物制剂靶向特定炎症通路作为全身泛免疫抑制替代方案的应用。生物制剂可能减少全身毒性并改善结局,随着免疫机制研究深入,其在皮肤科急症管理中的作用将日益增加。

要点

  • 生物制剂为皮肤科急症提供靶向治疗选择,可能减少全身泛免疫抑制的毒性。
  • 重点关注SJS/TEN、DRESS、寻常型天疱疮和泛发性脓疱型银屑病四类急症。
  • 生物制剂在住院皮肤科急症中的应用逐渐增多,需基于炎症通路选择。

核心结论

  • 生物制剂靶向特定炎症通路,可能作为皮肤科急症中全身泛免疫抑制的替代方案,减少毒性并改善结局。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 生物制剂在住院皮肤科急症中的应用逐渐增多,针对多种急症的特定炎症通路。
  • 生物制剂可能减少全身毒性并改善结局,随着免疫机制研究深入,其作用将日益增加。

临床怎么用

  • 本综述为皮肤科急症中生物制剂的使用提供实用指导,聚焦DRESS、SJS/TEN、寻常型天疱疮和泛发性脓疱型银屑病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dermatologic emergencies are frequently characterized by pathologic immune activation, necessitating systemic immunosuppression to reduce morbidity and mortality. Conventional management has largely relied on supportive care, avoidance of triggers (ie, inciting drugs), and/or systemic immunosuppression. However, advancements in therapeutics have unlocked new treatment options that can be especially beneficial in the acute setting. Specifically, biologic medications are increasingly being used by inpatient dermatologists to target specific inflammatory pathways implicated in many acute dermatologic emergencies. Biologics offer a targeted alternative to systemic pan-immunosuppression, potentially minimizing systemic toxicity and improving outcomes. As more studies outline the immune mechanisms driving dermatologic emergencies, biologics are likely to have an increasing role in managing these conditions. This review offers practical guidance on the use of biologics in dermatologic emergencies, with a focus on drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome/toxic epidermal necrolysis, pemphigus vulgaris, and generalized pustular psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Modanlo N, Cheng K, Nguyen MO, et al. Biologic therapies for dermatologic emergencies: A comprehensive review. J Am Acad Dermatol. 2025. PMID: 41110721. doi:10.1016/j.jaad.2025.10.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。